Centocor, Inc.’s sBLA for Remicade for the treatment of pediatric Crohn’s disease has been accepted and designated for Priority Review by the FDA. Centocor is seeking approval for the treatment of moderately to severely active pediatric Crohn’s disease in patients who have had an inadequate response to conventional therapies. Currently, there are no approved biologic therapies for the treatment of pediatric Crohn’s disease, a chronic, potentially debilitating condition th...